prev next front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |review
But we can do better than this. The cohort study gives us gold-standard mortality information. The cohort population confirms the period of increased mortality in early childhood and highlights an excess mortality rate compared to the clinic-based patients, which persists until early adulthood (Figure, regions A + C). This difference in mortality is likely to be the result of follow-up from birth among cohort patients and has been previously highlighted when examining the incidence of clinical events (1).

Reference

(1) Magnus SA, Hambleton IR, Moosdeen F, Serjeant GR. Recurrent infections in homozygous sickle cell disease. Arch Dis Child 1999; 80(6):537-541.